Previous studies suggest that the BCG vaccine could reduce susceptibility to a range of infections caused by viruses including those similar to the novel coronavirus causing COVID-19.
The DBT-BIRAC supported trial aims to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons of advanced age or co-morbidities and high-exposure healthcare workers.
Researchers found that countries with higher rates of Bacille Calmette-Guérin (BCG) vaccinations for tuberculosis had lower peak mortality rates from COVID-19.